warnings
WARNINGS: For external use only. Not for ophthalmic use.
Neurozyl
openFDA label record#
This page contains supplementary openFDA label data. For the canonical label presentation, use the corresponding DailyMed Structured Product Label.
Verified complete openFDA source JSON
- Brand name
- Neurozyl
- Generic name
- LIDOCAINE HCL 4.12 %
- Manufacturer
- PureTek Corporation
- Product type
- HUMAN PRESCRIPTION DRUG
- SPL set ID
- 1aca46c8-ff06-da0e-e063-6394a90a475f
- SPL ID
- 1aca46c8-ff05-da0e-e063-6394a90a475f
- Version
- 1
- Effective date
- 2024-06-13
- Source export date
- 2026-08-17
- Source partition
- 7
- Source file
- https://download.open.fda.gov/drug/label/drug-label-0007-of-0014.json.zip
- Source object key
- raw/openfda/drug-label/2026-08-17/1b5caad1d26c65d5be0ee71b8eb1373f0c7d99e6d83d2bfe99382f282ec02e02/drug-label-0007-of-0014.json.zip
- Source manifest SHA-256
- ca19d5b1416b6b66a9d383bfdc77d90e91adfeefe16ffcc1ac6b06ceb90d8d73
- Import run
- 20260818T065550Z
- Imported at
- 2026-08-18 07:37:01
| Harmonized routes |
|---|
| TOPICAL |
Harmonized identifier links#
Every typed identifier imported from the complete openFDA harmonization object is paginated here; values are not reduced to a first match.
| Type | Scope | Identifier | Source field |
|---|---|---|---|
| brand name | Neurozyl | openfda.brand_name | |
| generic name | LIDOCAINE HCL 4.12 % | openfda.generic_name | |
| manufacturer name | PureTek Corporation | openfda.manufacturer_name | |
| ndc | package | 59088-321-07 | openfda.package_ndc |
| ndc | product | 59088-321 | openfda.product_ndc |
| ndc11 | package | 59088032107 | derived:openfda.package_ndc |
| rxcui | 1947197 | openfda.rxcui | |
| spl id | 1aca46c8-ff05-da0e-e063-6394a90a475f | id | |
| spl set id | 1aca46c8-ff06-da0e-e063-6394a90a475f | set_id | |
| unii | V13007Z41A | openfda.unii |
Warnings cross-check#
openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.
Adverse reactions cross-check#
openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.
adverse reactions
ADVERSE REACTIONS: During or immediately after treatment, the skin at the site of treatment may develop erythema or edema or may be the locus of abnormal sensation.